Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: ENSC) | Delayed: 0.49 -0.02 (3.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.51 | 52 Week High | $ | |||
| Open | $0.52 | 52 Week Low | $ | |||
| Day High | $0.52 | P/E | N/A | |||
| Day Low | $0.48 | EPS | $ | |||
| Volume | 121,219 | |||||
